| Oct 3 |
AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
|
| Oct 3 |
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
|
| Oct 3 |
Owkin and AstraZeneca to develop AI tool for breast cancer testing
|
| Oct 3 |
Arcus and AstraZeneca enter trial collaboration for renal cancer treatment
|
| Oct 3 |
3 UK Stocks Estimated To Be Trading Below Their Intrinsic Value
|
| Oct 1 |
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
|
| Oct 1 |
AstraZeneca's Enhertu application accepted by FDA with priority review
|
| Oct 1 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
|
| Oct 1 |
5 FDA decisions to watch in the fourth quarter
|
| Sep 30 |
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
|
